International consensus guidelines for the treatment of problem bleeds by Teitel et al.

To optimise patient care, an international panel of physicians developed a consensus algorithm to aid physicians in considering a variety of treatment approaches for problem bleeds in haemophilia patients with inhibitors.1

The guidelines suggest that after initiating treatment with one bypassing agent, evaluate patient response frequently and make early therapy adjustment at the first sign of unsatisfactory haemostatic response. Optimising the timing of treatment decisions with early therapy adjustment may lead to faster responses and improved outcomes.1

The guidelines provide a generalised methodology to guide the treatment of both life-threatening and limb-threatening bleeds.1

The risk of a potential interaction between rFVIIa and coagulation factor concentrates is unknown. Simultaneous use of prothrombin complex concentrates, activated or not, should be avoided.

Consult the Prescribing Information for FEIBA and rFVIIa for the approved dosing.

Reference

  1. 1. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007:13:256-263.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven in on-demand therapy

Learn about the efficacy of FEIBA in on-demand treatment. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more